From 2004 through 2014, Mr. Young served as Gilead’s Executive Vice President of Commercial Operations. Since 2014, he has held the role of senior advisor to the company.
Prior to Gilead, he spent more than 20 years in the biopharmaceutical industry, first with ICI Pharmaceuticals and subsequently with Amgen. Mr. Young has undergraduate and graduate degrees in Sports Science and Exercise from Liverpool and Nottingham, England.
In 2011, he was appointed a Commander of The British Empire, one of Great Britain’s highest civilian honors, in recognition of his “services to the healthcare and pharmaceutical industries.”
Dr. Silverstein will oversee Gilead’s corporate development, commercial planning and alliance management functions. He previously held the role of Executive Vice President and Chief Strategy Officer at Anthem from April 2014 through December 2015.
Prior to Anthem, Dr. Silverstein spent 28 years in roles of increasing responsibility at The Boston Consulting Group, including serving as Global Leader of its Health Care Practice, Senior Partner and Managing Director.
He received a medical degree from Yale University, an MBA from Harvard Business School and a bachelor’s degree from the University of Pennsylvania. He completed his internal medicine residency at Boston's Beth Israel Hospital and is board certified in Internal Medicine.
The company also announced that Paul R. Carter, Executive Vice President, Commercial Operations, has decided to depart Gilead and pursue other opportunities. ■
LATEST MOVES FROM California
- Reed's appoints Stefan Freeman as interim CEO
- Heron Therapeutics appoints Robert E. Hoffman as CFO
- Penumbra appoints Bridget O'Rourke to board
- Adverum Biotechnologies adds Richard N. Spivey to board
- Lombard Medical appoints Kurt Lemvigh as CEO
More inside POST
What to do with slowly-developing talents Leadership